HUTCHMED (China) Limited
HCM
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $2.5B
$14.09
▼ -0.14%
P/E
144.51
Mkt Cap
$2.5B
52-Wk Range
$9.77–$18.30
52-Week Range
$9.77 - $18.30
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 12.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
2 risks
- Low volatility (beta 0.4).
- High premium - requires strong execution
Growth
Strong growth ahead
Value
High premium - requires strong execution
Momentum
Hot
+29.9% over 3m
Quality
Thin
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying HCM right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
JUL 30, 2026
Reported EPS of $0.05 vs $0.15 consensus (-68.3% surprise). Revenue of $278.3M vs $304.2M expected (-8.5%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-68.3%
Revenue trend · last 3Q
-17%
—
+0%
Q4 25
Q1 26
Q2 26
$135.4M
$139.1M
$139.1M
Margins · last 3Q
Gross
17.0%
Operating
0.3%
Profit
5.7%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Daiwa Capital · Sep 3, 2026
vs Industry
How HCM stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.